Eledon Pharmaceuticals Inc (ELDN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.62 (-1.13%), Market cap $0.29B, 52-week low–high $1.39 ~ $4.36.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. fo
Financial statements, price targets, institutional (13F) holdings and related news for Eledon Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Eledon Pharmaceuticals Inc trades at $2.62 (-1.13%). Real-time quotes and charts are available on BlackAll Trade.
Eledon Pharmaceuticals Inc has a market cap of about $0.29B.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplan